US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
16/12/19 - 14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products
Molecular
06/12/19 - 18:12
Press Release (262.61 KB)
Other
06/12/19 - 18:11
Press Release (262.7 KB)
Other
06/12/19 - 18:08
Communication on total amount of voting rights (281.87 KB)
Other
27/11/19 - 7:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products
Immunodiagnostic
11/11/19 - 9:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products
Molecular
06/11/19 - 13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data
30/10/19 - 9:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products
Immunodiagnostic
22/10/19 - 14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products
Immunodiagnostic
07/10/19 - 10:20
Communication on total amount of voting rights (282.21 KB)
Other
24/09/19 - 10:10
DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products
Molecular
31/07/19 - 13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data
10/06/19 - 18:23
DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data
05/06/19 - 7:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
Acquisition / Partnership
Immunodiagnostic
29/05/19 - 15:06
DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products
Molecular
09/05/19 - 13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data
06/05/19 - 15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products
Immunodiagnostic
30/04/19 - 12:28
Update Annual Calendar of Corporate Events 2019 (249.43 KB)
Other
24/04/19 - 17:24
DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
Other
12/04/19 - 8:59
Communication on total amount of voting rights (320.44 KB)
Other
05/04/19 - 9:33
Communication on total amount of voting rights (342.47 KB)
Other
03/04/19 - 20:18
Lists publication (79.68 KB)
Other
03/04/19 - 10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products
Immunodiagnostic
14/03/19 - 14:16
Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data
07/03/19 - 11:45
Communication on total amount of voting rights (350.08 KB)
Other
06/03/19 - 8:45
A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
Other
07/02/19 - 15:15
Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
Other
31/01/19 - 22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products
Immunodiagnostic
03/01/19 - 13:30
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products
Molecular